Infections during treatment with biological agents and possible treatment in clinical practice

Expert Review of Clinical Immunology

Volumn 9, Issue 3, 2013, Pages 193-195

  Atzeni, Fabiola ^a   Benucci, Maurizio ^b   Sarzi Puttini, Piercarlo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

Author keywords

anti CD20 antibodies; anti TNF drugs; infections

Indexed keywords

ABATACEPT; BIOLOGICAL PRODUCT; CD20 ANTIBODY; CYTOTOXIC AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ASPERGILLOSIS; BACTERIAL ARTHRITIS; BACTERIAL INFECTION; CLINICAL PRACTICE; DRUG COST; DRUG WITHDRAWAL; EXTRAPULMONARY TUBERCULOSIS; HEART FAILURE; HEPATITIS B; HEPATITIS C; HERPES ZOSTER; HOST RESISTANCE; HUMAN; IMMUNE SYSTEM; INFECTION; LISTERIOSIS; MORBIDITY; MORTALITY; NOCARDIOSIS; NONHUMAN; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SALMONELLOSIS; SEPSIS; SKIN INFECTION; SOFT TISSUE INFECTION; SPONDYLARTHRITIS; TUBERCULOSIS; URINARY TRACT INFECTION; VIRUS REACTIVATION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BACTERIAL INFECTIONS; BIOLOGICAL AGENTS; HUMANS; IMMUNOLOGIC FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VIRUS DISEASES;

EID: 84874629760     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/eci.13.3     Document Type: Review

References (25)

1. Thompson AE, Rieder SW, Pope JE. Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a metaanalysis of randomized controlled trials. Arthritis Rheum. 63(6), 1479-1485 (2011).
2. Caporali R, Pallavicini FB, Filippini M et al. Treatment of rheumatoid arthritis with anti- TNF-α agents: a reappraisal. Autoimmun. Rev. 8(3), 274-280 (2009).
3. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 46(9), 2287-2293 (2002).
4. Dixon WG,Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 54(8), 2368-2376 (2006).
5. Listing J, Strangfeld A, Kary S et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 52(11), 3403-3412 (2005).
6. Galloway JB, Hyrich KL, Mercer LK et al.; BSRBR Control Centre Consortium; British Society for Rheumatology Biologics Register. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 50(1), 124-131 (2011).
7. Strangfeld A, Eveslage M, Schneider M et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann. Rheum. Dis. 70(11), 1914-1920 (2011).
8. Atzeni F, Sarzi-Puttini P, Botsios C et al. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun. Rev. 12(2), 225-229 (2012).
9. Filippini M, Bazzani C, Favalli EG et al. Efficacy and safety of anti-tumour necrosis factor in elderly patients with rheumatoid arthritis: an observational study. Clin. Rev. Allergy Immunol. 38(2-3), 90-96 (2010).
10. Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat. Clin. Pract. Rheumatol. 2(11), 602-610 (2006).
11. Keane J, Bresnihan B. Tuberculosis reactivation during immunosuppressive therapy in rheumatic diseases: diagnostic and therapeutic strategies. Curr. Opin. Rheumatol. 20(4), 443-449 (2008).
12. Smith MY, Attig B, McNamee L, Eagle T. Tuberculosis screening in prescribers of anti-tumor necrosis factor therapy in the European Union. Int. J. Tuberc. Lung Dis. 16(9), 1168-1173 (2012).
13. Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP. Fungal infections complicating tumor necrosis factor α blockade therapy. Mayo Clin. Proc. 83(2), 181-194 (2008).
14. Alvarez B, Arcos J, Fernández-Guerrero ML. Pulmonary infectious diseases in patients with primary immunodeficiency and those treated with biologic immunomodulating agents. Curr. Opin. Pulm. Med. 17(3), 172-179 (2011).
15. Zisman D, Haddad A, Hashoul S et al. Hospitalizations of patients treated with anti-tumor necrosis factor-a agents - a retrospective cohort analysis. J. Rheumatol. 40(1), 16-22 (2013).
16. Galloway JB, Hyrich KL, Mercer LK et al.; BSR Biologics Register. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann. Rheum. Dis. 70(10), 1810-1814 (2011).
17. Goh L, Jewell T, Laversuch C, Samanta A. Should anti-TNF therapy be discontinued in rheumatoid arthritis patients undergoing elective orthopaedic surgery? A systematic review of the evidence. Rheumatol. Int. 32(1), 5-13 (2012).
18. Davies R, Dixon WG, Watson KD, Lunt M, Symmons DP, Hyrich KL; BSRBR Control Centre Consortium on behalf of the BSRBR. Influence of anti-TNF patient warning regarding avoidance of high risk foods on rates of listeria and salmonella infections in the UK. Ann. Rheum. Dis. 72(3), 461-462 (2012).
19. Zhang J, Xie F, Delzell E et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA 308(1), 43-49 (2012).
20. Wendling D, Auge B, Bettinger D et al. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann. Rheum. Dis. 64(5), 788-789 (2005).
21. Caporali R, Bobbio-Pallavicini F, Atzeni F et al. Safety of tumor necrosis factor α blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/ anti-hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care Res. (Hoboken) 62(6), 749-754 (2010).
22. Parke FA, Reveille JD. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum. 51(5), 800-804 (2004).
23. Atzeni F, Sarzi-Puttini P, Mutti A, Bugatti S, Cavagna L, Caporali R. Long-term safety of abatacept in patients with rheumatoid arthritis. Autoimmun. Rev. (2013) (In Press).
24. van Vollenhoven RF, Emery P, Bingham CO 3rd et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann. Rheum. Dis. doi:10.1136/ annrheumdis-2012-201956 (2012) (Epub ahead of print).
25. Benucci M, Saviola G, Baiardi P, Manfredi M, Sarzi Puttini P, Atzeni F. Determinants of risk infection during therapy with anti TNF-α blocking agents in rheumatoid arthritis. Open Rheumatol. J. 6, 33-37 (2012).